<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharma Watchdog &#187; Leukine</title>
	<atom:link href="http://www.pharmawatchdog.com/tag/leukine-defective-drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmawatchdog.com</link>
	<description>Law Offices of Sadaka Associates</description>
	<lastBuildDate>Sat, 21 Aug 2010 12:08:29 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Leukine (sargramostim)</title>
		<link>http://www.pharmawatchdog.com/drug-safety-news/leukine-sargramostim-2/</link>
		<comments>http://www.pharmawatchdog.com/drug-safety-news/leukine-sargramostim-2/#comments</comments>
		<pubDate>Wed, 27 Feb 2008 06:05:40 +0000</pubDate>
		<dc:creator>Sadaka Associates</dc:creator>
				<category><![CDATA[Bayer]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Leukine]]></category>
		<category><![CDATA[Syncope]]></category>

		<guid isPermaLink="false">http://www.pharmawatchdog.com/2008/02/27/leukine-sargramostim-2/</guid>
		<description><![CDATA[Bayer and FDA informed healthcare professionals of the market withdrawal of the current liquid formulation of Leukine, a growth factor that helps fight infection and disease in appropriate patients by enhancing immune cell function. The product was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally [...]]]></description>
			<content:encoded><![CDATA[<p>Bayer and FDA informed healthcare professionals of the market withdrawal of the current liquid formulation of Leukine, a growth factor that helps fight infection and disease in appropriate patients by enhancing immune cell function. The product was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change in the formulation of liquid Leukine to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates has not been observed with the use of lyophilized Leukine. Healthcare professionals should immediately stop using liquid Leukine and return unused vials to the manufacturer.</p>
<dl></dl>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmawatchdog.com/drug-safety-news/leukine-sargramostim-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leukine (sargramostim)</title>
		<link>http://www.pharmawatchdog.com/drug-safety-news/leukine-sargramostim/</link>
		<comments>http://www.pharmawatchdog.com/drug-safety-news/leukine-sargramostim/#comments</comments>
		<pubDate>Mon, 28 Jan 2008 18:26:55 +0000</pubDate>
		<dc:creator>Sadaka Associates</dc:creator>
				<category><![CDATA[Fainting]]></category>
		<category><![CDATA[Leukine]]></category>
		<category><![CDATA[Syncope]]></category>

		<guid isPermaLink="false">http://www.pharmawatchdog.com/2008/01/28/leukine-sargramostim/</guid>
		<description><![CDATA[Bayer and FDA informed healthcare professionals of the market withdrawal of the current liquid formulation of Leukine, a growth factor that helps fight infection and disease in appropriate patients by enhancing immune cell function. The product was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally [...]]]></description>
			<content:encoded><![CDATA[<p>Bayer and FDA informed healthcare professionals of the market withdrawal of the current liquid formulation of Leukine, a growth factor that helps fight infection and disease in appropriate patients by enhancing immune cell function. The product was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change in the formulation of liquid Leukine to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates has not been observed with the use of lyophilized Leukine. Healthcare professionals should immediately stop using liquid Leukine and return unused vials to the manufacturer.</p>
<dl></dl>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmawatchdog.com/drug-safety-news/leukine-sargramostim/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
